Ignite Creation Date:
2024-05-06 @ 10:09 AM
Last Modification Date:
2024-10-26 @ 12:25 PM
Study NCT ID:
NCT03175731
Status:
COMPLETED
Last Update Posted:
2021-06-09
First Post:
2017-05-25
Brief Title:
PPIs and Gastroesophageal Varices in Liver Cirrhosis PPIs Proton Pump Inhibitors
Sponsor:
Yanjing Gao
Organization:
Qilu Hospital of Shandong University
Study Overview
Official Title:
A Randomized Controlled Study on the Effects of PPIs on Gastroesophageal Variceal Bleeding in Liver Cirrhosis PPIs Proton Pump Inhibitors
Status:
COMPLETED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PPIs
Brief Summary:
This study is aimed at investigating the effect of PPIs on gastroesophageal varices in liver cirrhosis Half of participants will receive PPI while the other half will receive a placebo
Detailed Description:
PPIs can inhibit parietal cell HK-ATPase and reduce secretion of gastric acid PPIs can promote platelet aggregation and stabilize the formation of fibrin thrombosis by maintaining the high pH environment in the stomach and inactivating pepsin The effect of PPIs on ulcerative upper gastrointestinal bleeding was confirmed but it is not clear whether PPIs is applicable in esophagogastric variceal bleeding whose etiology and bleeding position are different from ulcerative upper gastrointestinal bleeding There is lack of consensus and sufficient evidences to support to use PPIs in esophagogastric variceal bleeding in cirrhotic patients universally Nevertheless the use of PPIs in liver cirrhotic patients with gastroesophageal varices is common
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None